KR101894829B1 - 상처 치유를 촉진하기 위한 짧은 생체-활성 펩티드 - Google Patents

상처 치유를 촉진하기 위한 짧은 생체-활성 펩티드 Download PDF

Info

Publication number
KR101894829B1
KR101894829B1 KR1020157024070A KR20157024070A KR101894829B1 KR 101894829 B1 KR101894829 B1 KR 101894829B1 KR 1020157024070 A KR1020157024070 A KR 1020157024070A KR 20157024070 A KR20157024070 A KR 20157024070A KR 101894829 B1 KR101894829 B1 KR 101894829B1
Authority
KR
South Korea
Prior art keywords
peptides
peptide
skin
seq
wound healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157024070A
Other languages
English (en)
Korean (ko)
Other versions
KR20150116883A (ko
Inventor
리주안 장
로빈 카마이클
Original Assignee
헬릭스 바이오메딕스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헬릭스 바이오메딕스, 인코포레이티드 filed Critical 헬릭스 바이오메딕스, 인코포레이티드
Publication of KR20150116883A publication Critical patent/KR20150116883A/ko
Application granted granted Critical
Publication of KR101894829B1 publication Critical patent/KR101894829B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Birds (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Insects & Arthropods (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
KR1020157024070A 2013-02-14 2014-01-21 상처 치유를 촉진하기 위한 짧은 생체-활성 펩티드 Expired - Fee Related KR101894829B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764913P 2013-02-14 2013-02-14
US61/764,913 2013-02-14
PCT/US2014/012378 WO2014126681A1 (en) 2013-02-14 2014-01-21 Short bio-active peptides for promoting wound healing

Publications (2)

Publication Number Publication Date
KR20150116883A KR20150116883A (ko) 2015-10-16
KR101894829B1 true KR101894829B1 (ko) 2018-09-05

Family

ID=50069319

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024070A Expired - Fee Related KR101894829B1 (ko) 2013-02-14 2014-01-21 상처 치유를 촉진하기 위한 짧은 생체-활성 펩티드

Country Status (23)

Country Link
US (2) US9487558B2 (enExample)
EP (1) EP2956155B1 (enExample)
JP (1) JP6348126B2 (enExample)
KR (1) KR101894829B1 (enExample)
CN (1) CN105120884B (enExample)
AR (1) AR094835A1 (enExample)
AU (1) AU2014216730B2 (enExample)
BR (1) BR112015019568A2 (enExample)
CA (1) CA2898717C (enExample)
CY (1) CY1119087T1 (enExample)
DK (1) DK2956155T3 (enExample)
ES (1) ES2633437T3 (enExample)
HU (1) HUE033976T2 (enExample)
MX (1) MX363955B (enExample)
MY (1) MY173174A (enExample)
NZ (1) NZ711281A (enExample)
PL (1) PL2956155T3 (enExample)
RU (1) RU2606753C1 (enExample)
SG (1) SG11201505538QA (enExample)
SI (1) SI2956155T1 (enExample)
TW (1) TWI587867B (enExample)
WO (1) WO2014126681A1 (enExample)
ZA (1) ZA201505516B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019519596A (ja) * 2016-04-08 2019-07-11 コーネル・ユニバーシティーCornell University シルク由来タンパク質を使用して創傷治癒を増進する方法
EP3312608B1 (en) * 2016-10-24 2019-10-02 Akribes Biomedical GmbH Methods for identifying a non-healing skin wound and for monitoring the healing of a skin wound
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
CN108586575B (zh) * 2018-04-11 2020-08-14 福建省中科生物股份有限公司 一种多肽及其皮肤修复功能的应用
CZ308845B6 (cs) * 2019-01-21 2021-07-07 Globetech Innovation S.R.O Farmaceutická směs topicky hojivých peptidových složek pro použití k topické léčbě kožních defektů a/nebo k topickému hojení ran
CN116407611A (zh) * 2021-12-29 2023-07-11 四川好医生攀西药业有限责任公司 一种多肽在制备预防或治疗皮肤损伤疾病产品上的应用
WO2025215346A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Skin wound treatment
WO2025215347A1 (en) * 2024-04-08 2025-10-16 The Boots Company Plc Skin wound treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696174B2 (en) 2007-01-05 2010-04-13 Helix Biomedix, Inc. Short bio-active peptides for cellular and immunological modulation
US20140255299A1 (en) 2011-08-25 2014-09-11 University Of Central Florida Research Foundation, Inc. Methods and Compositions Comprising a C-Terminal Bax Peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360939A (ja) * 1986-08-29 1988-03-17 Shin Etsu Chem Co Ltd 抗菌物質
DE3854476T2 (de) 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
EP3002294B8 (en) * 2006-06-13 2018-05-16 Helix Biomedix Inc. Peptide fragments for inducing synthesis of extracellular matrix proteins
RU2447896C1 (ru) * 2010-11-15 2012-04-20 Общество с ограниченной ответственностью "Аллофарм" Антимикробное вещество

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696174B2 (en) 2007-01-05 2010-04-13 Helix Biomedix, Inc. Short bio-active peptides for cellular and immunological modulation
US20140255299A1 (en) 2011-08-25 2014-09-11 University Of Central Florida Research Foundation, Inc. Methods and Compositions Comprising a C-Terminal Bax Peptide
US9040662B2 (en) 2011-08-25 2015-05-26 University Of Central Florida Research Foundation Methods and compositions comprising a C-terminal Bax peptide
US20150359841A1 (en) 2011-08-25 2015-12-17 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising a c-terminal bax peptide

Also Published As

Publication number Publication date
TWI587867B (zh) 2017-06-21
MX363955B (es) 2019-04-08
CA2898717C (en) 2019-01-08
MX2015009404A (es) 2016-10-07
BR112015019568A2 (pt) 2017-08-22
WO2014126681A1 (en) 2014-08-21
ZA201505516B (en) 2016-10-26
CY1119087T1 (el) 2018-01-10
EP2956155B1 (en) 2017-04-19
CA2898717A1 (en) 2014-08-21
ES2633437T3 (es) 2017-09-21
SG11201505538QA (en) 2015-08-28
DK2956155T3 (en) 2017-07-31
NZ711281A (en) 2017-12-22
US20170000848A1 (en) 2017-01-05
JP2016513107A (ja) 2016-05-12
AU2014216730A1 (en) 2015-08-20
JP6348126B2 (ja) 2018-06-27
HK1212243A1 (en) 2016-06-10
US20150353605A1 (en) 2015-12-10
MY173174A (en) 2020-01-02
RU2606753C1 (ru) 2017-01-10
AR094835A1 (es) 2015-09-02
SI2956155T1 (sl) 2017-10-30
AU2014216730B2 (en) 2015-12-17
HUE033976T2 (en) 2018-02-28
TW201446258A (zh) 2014-12-16
US9487558B2 (en) 2016-11-08
CN105120884A (zh) 2015-12-02
KR20150116883A (ko) 2015-10-16
CN105120884B (zh) 2017-08-29
EP2956155A1 (en) 2015-12-23
PL2956155T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
KR101894829B1 (ko) 상처 치유를 촉진하기 위한 짧은 생체-활성 펩티드
KR102254260B1 (ko) 다양한 피부 병태의 치료에 유용한 인간 c-x-c 케모카인으로부터 유래된 테트라펩타이드
CN103249426A (zh) 用于治疗创伤的方法和包括富组蛋白5环状类似物的组合物
HK1212243B (en) Short bio-active peptides for promoting wound healing
ZHANG et al. GCC PATENT APPLICATION
HK1217436B (en) Tetrapeptides derived from human c-x-c chemokines useful for treatment of various skin conditions

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210830

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210830